← Leaderboards
Elisabetta Morini
Montana State University - Bozeman
$1,752,530
Attributed
$3,650,496
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,650,496 · 4
By mechanism
R01$2,963,690 · 2
R21$686,806 · 2
Top collaborators
- Maria Catarina Telo Baptista Lima Da Silva4 shared
- Frances Lefcort2 shared
- Claudio Punzo2 shared
- Susan A Slaugenhaupt2 shared
- Christiano Alves1 shared
Most similar at Montana State University - Bozeman
Same institution · by research overlap
- Valerie Copie$1,960,906
- Lynn D George$1,265,333
Others in their field
Other Emerging Leaders on “Exon Skipping”
- Rendong Yang · University Of Minnesota$3,433,997
- Uwe Beffert · Boston University (Charles River Campus)$2,397,445
- Nicholas Andrew Geisse · Curi Bio Inc$2,306,784
- Georg Seelig · University Of Washington$2,034,802
- Reyad A Elbarbary · Pennsylvania State Univ Hershey Med Ctr$1,948,116
- Matthew Scott Alexander · University Of Alabama At Birmingham$1,870,554
Research focus
Exon SkippingProteinsPhenotypeMutationFamilial DysautonomiaRna SplicingNervous System DisorderNeuronsMutantGenesTissuesDefectAffectNeurodegenerative DisordersDisease PhenotypeNerve DegenerationPathogenesisMolecularIn VitroMediatingExonsMessenger RnaGene Expression RegulationBrain
Grant awards (9)
Understanding Neuronal Cell type-Specific Dysregulation in Familial Dysautonomia$631,395
R01 · FY2025 · NS
Developing Splicing-Targeted Therapeutic Strategies for Neurological Diseases$420,000
R01 · FY2025 · NS · contact PI
A one and done therapeutic strategy to correct ELP1 splicing defect in familial dysautonomia$250,500
R21 · FY2025 · EY · contact PI
Understanding neuronal cell type-specific dysregulation in familial dysautonomia$664,895
R01 · FY2024 · NS
Developing Splicing-Targeted Therapeutic Strategies for Neurological Diseases$407,400
R01 · FY2024 · NS · contact PI
Developing Splicing-Targeted Therapeutic Strategies for Neurological Diseases$420,000
R01 · FY2023 · NS · contact PI
Developing splicing-targeted therapeutic strategies for neurological diseases$420,000
R01 · FY2022 · NS · contact PI
Therapeutic strategies for mitigating loss of retinal ganglion cells in familial dysautonomia$186,442
R21 · FY2021 · EY
Therapeutic strategies for mitigating loss of retinal ganglion cells in familial dysautonomia$249,864
R21 · FY2020 · EY